Loading...

IOLCP IOL Chemicals & Pharmaceuticals Ltd Quarterly Earnings Reports Announcement

L Ch

LCP

IOL Chemicals & Pharmaceuticals Ltd

(IOLCP)

2025 Announcement

CEP Certification

Regulatory notice

Earnings Call Transcript

Geographic Expansion

Newspaper Publication

Q2 FY26 Results

Unaudited Results

Unaudited Results

Investor Conference Call

Board Meeting Notice

CEP Certificate Issued

New Subsidiary Incorporated

Share Acquisition

CEP Certificate Issued

Compliance Certificate

Transfer Requests Update

Newspaper Publication

KYC Update Reminder

Investor Meeting

Volume Movement Clarification

100-Day Campaign

Earnings Call Transcript

Investor Meetings

Investor Meeting Schedule

Investor Call Summary

Quarterly Results

Investor Presentation

Q1 Earnings Report

Shareholder Update

Investor Conference Call

Notice Publication

AGM Notice Published

Investor Meeting

Annual Meeting Notice

Compliance Certificate

Credit Rating Reaffirmed

REACH Registration

EcoVadis Silver Medal

Earnings Call Transcript

Investor Call Recording

Investor Presentation

Newspaper Publication

Management Changes

Q4 Financial Results

Annual Compliance Report

Investor Conference Call

Ibuprofen Approval

Gas Leak Incident

Compliance Certificate

Investor Meet Schedule

Facility Expansion

Investor Meet Scheduled

Regulatory Fine Paid

CEP Certificate Issued

Q3 FY25 Results

Dividend Record Date

Investor Call Recording

TDS Communication

Q3 FY2025 Presentation

Financial Results Published

Q3 FY25 Results

Investor Conference Call

Share Split Approval

CEP Certificate Issued

Compliance Certificate

Postal Ballot Notice

Board Comments On Fine

Responsible Care Award

Investor Meeting Scheduled

Regulatory Fine Imposed

Earnings Call Transcript

Investor Call Recording

Q2 FY2025 Presentation

Financial Results Published

Financial Results FY25

Investor Meeting Scheduled

Postal Ballot Notice

Investor Call Scheduled

Credit Rating Reaffirmed

Management Change

Regulatory Certificate

KYC Update Reminder

Investor Meeting

CEO Resignation

Earnings Call Transcript

Analyst Call Recording

Investor Presentation

Financial Results Update

Financial Results Announcement

Management Change

Conference Call Intimation

Notice published in Newspapers

CEP Certificate

Certificate Submission

Approval Announcement

Credit Rating Reaffirmed

Schedule of Analyst/Institu...

CEP Certificate Received

CEP Certificate Announcement

Earnings Call Transcript

Audio Recording

Investor Presentation

Financial Results Publication

Financial Results Announcement

Conference Call

Compliance Report

Certificate Issued

Certificate Submission

Compliance Certificate

Certificate Submission

CEP Certificate Issued

Site Inspection Completion

Meeting Participation

Product Approval

Tax Deduction on Interim Di...

Investor Presentation

Financial Results Publication

Financial Results Announcement

Certificate Received

Conference Call

Certificate Compliance

Meeting Schedule

Meeting Scheduled

Earnings Conference Call Tr...

Intimation Under Regulation...

Audio Recording Release

published newspaper publica...

Investor Presentation

Financial Results

Conference Call

Compliances-Certificate

Plant Visit for Analysts

Meeting Schedule

Meeting Scheduled

Analyst/Investor Meeting

Financial Statements

Financial Statements

Financial Statements

Financial Statements, Earni...

Financial Statements

Outlook Changes

Product Expansion

Analyst/Investor Meeting

Management Changes

Analyst/Investor Meeting

Financial Statements

Conference Call

Equity, Debt, VC, Private E...

Notice Publication

Management Changes

External Links:

Data:

IOL Chemicals & Pharmaceuticals Ltd reports a revenue of ₹551.7 Cr and a profit after tax of ₹34.0 Cr for Q1 FY26, marking a growth of 9.8% and 14.4% respectively compared to the same quarter last year, as announced on 7th August 2025.

AI Assistant

IOL Chemicals & Pharmaceuticals Ltd

2025

Announcement

Find Answers

Ask about any part of the document to get insights, explanations, or key details.